- Pharmaceutical Group Diurnal said its congenital adrenal drug, Chronocort, had been the granted a second US patent by US Patent and Trademark Office.

The patent, US 10,166,194, entitled 'Hydrocortisone Controlled Release Formulatio'", claimed a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia and adrenal insufficiency, that delivered hydrocortisone in accordance with a circadian rhythm.

The patent would provide in-market protection until 2033 and comes after the company was granted a pharmaceutical composition of matter patent, US 9,750,704, which provided in-market protection until 2034.

The US is expected to be a major territory for sales of Chronocort, with the congenital adrenal hyperplasia and adrenal insufficiency addressable market estimated at about $1bn.

'With patents now extending protection in the US for both Chronocort and our paediatric product Alkindi to 2034, we are confident that, if approved, these products will enjoy a long period of exclusivity in the US market and provide the potential for lifelong treatment of patients with CAH and AI,' said Martin Whitaker, CEO of Diurnal.

At 10:31am: [LON:DNL] Diurnal Group Plc share price was +25p at 46.5p

Story provided by